EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Patterns of progression and efficacy of immune checkpoint inhibitors in unresectable, recurrent, or metastatic cholangiocarcinoma: A real-world study

Yupeng Li, Yiming Mu, Fengxue Li, Jiandong Zhang, Jingxin Zhang, Lili Qiao, Yamin Zhang

Digestive and Liver Disease · 2026-10 · 58 (10) · 1339-1348

DOI: 10.1016/j.dld.2026.07.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive and Liver Disease, 2026-10. Verfasst von Yupeng Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: First Central Hospital of Tianjin Medical University, Tianjin, China; Department of Oncology, The First Affiliated Hospital of Shandong First Medical…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Immune Checkpoint Inhibitors, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: To characterize the progression patterns and analyze the efficacy of immune checkpoint inhibitors (ICIs) in unresectable, recurrent, or metastatic cholangiocarcinoma (CCA). METHODS: A retrospective analysis was conducted in CCA patients treated with ICIs between September 2019 and September 2024. The progression patterns of ICIs were assessed, and survival and prognostic factors were analyzed using Kaplan-Meier and Cox regression models. RESULTS: Among 131 eligible patients, the median overall survival (OS) and progression-free survival (PFS) were 14.1 and 7.9 months, respectively. Multivariable Cox analysis identified lung metastasis, absent abdominal lymph node/retroperitoneal lymph node (LN/RPLN) metastasis, and CA199 ≥ 35 U/ml as independent predictors of shorter PFS, and smoking, no surgery, and CA199 ≥ 35 U/ml as predictors of shorter OS (all p < 0.05). Rising CA199 correlated with poorer PFS (p < 0.05). Progression occurred in 80 patients, 77.5% within 12 months. Oligo-progression was the main pattern (53.8%). Liver (43.8%) and abdominal LN/RPLN (38.8%) were the most common sites of progression. Oligo-progression was associated with superior OS versus systemic progression (median 22.7 vs. 11.7 months, p = 0.003). Among oligo-progression patients, local plus systemic therapy showed a trend toward better OS than systemic therapy alone (28.9 vs. 15.8 months, p = 0.062). CONCLUSIONS: ICIs demonstrate meaningful efficacy in CCA. Oligo-progression represents the predominant failure pattern and is associated with favorable prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaBile Duct NeoplasmsImmune Checkpoint InhibitorsNeoplasm Recurrence, LocalHumansRetrospective StudiesFemaleMaleDisease ProgressionAgedMiddle AgedPrognosisProgression-Free SurvivalAntigens, Tumor-Associated, Carbohydrate

Stichwörter der Autor:innen

CholangiocarcinomaImmune checkpoint inhibitorsPrognosisProgression patterns

Substanzen

Immune Checkpoint InhibitorsAntigens, Tumor-Associated, Carbohydrate

Autor:innen und Institutionen

  • First Central Hospital of Tianjin Medical University, Tianjin, China; Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shando…
  • Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
  • Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. Electronic address: zsln2020@163.com.
  • Department of Oncology, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China. Electronic address: qiaolili523@126.com.
  • First Central Hospital of Tianjin Medical University, Tianjin, China. Electronic address: 5020200824@nankai.edu.cn.

Zitieren

APA

Li, Y., Mu, Y., Li, F., Zhang, J., Zhang, J., Qiao, L., & Zhang, Y. (2026). Patterns of progression and efficacy of immune checkpoint inhibitors in unresectable, recurrent, or metastatic cholangiocarcinoma: A real-world study. Digestive and Liver Disease, 58(10), 1339-1348. https://doi.org/10.1016/j.dld.2026.07.013

Vancouver

Li Y, Mu Y, Li F, Zhang J, Zhang J, Qiao L, et al. Patterns of progression and efficacy of immune checkpoint inhibitors in unresectable, recurrent, or metastatic cholangiocarcinoma: A real-world study. Digestive and Liver Disease. 2026;58(10):1339-1348. doi:10.1016/j.dld.2026.07.013

BibTeX
@article{Li2026,
  author = {Li, Yupeng and Mu, Yiming and Li, Fengxue and Zhang, Jiandong and Zhang, Jingxin and Qiao, Lili and Zhang, Yamin},
  title = {Patterns of progression and efficacy of immune checkpoint inhibitors in unresectable, recurrent, or metastatic cholangiocarcinoma: A real-world study},
  journal = {Digestive and Liver Disease},
  year = {2026},
  volume = {58},
  number = {10},
  pages = {1339--1348},
  doi = {10.1016/j.dld.2026.07.013}
}
Kostenlos starten →